Stock CW9 COMPUGEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Compugen Ltd. Deutsche Boerse AG

Equities

CW9

IL0010852080

Real-time Estimate Tradegate
Other stock markets
 10:26:50 2024-07-17 EDT 		5-day change 1st Jan Change
1.705 EUR -66.24% Intraday chart for Compugen Ltd. -9.82% 0.00%
06-27 Transcript : Compugen Ltd. - Special Call
05-30 Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compugen to Present at Upcoming Antibody Industrial Symposium
PR
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
PR
Compugen : Reports First Quarter 2024 Results
PU
Compugen: Q1 Earnings Snapshot
AQ
Compugen Reports First Quarter 2024 Results
PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
PU
Compugen Appoints David Silberman as Chief Financial Officer
PR
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
PU
Compugen to Participate in Two Upcoming Investor Conferences
PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PR
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
PU
Compugen: Q4 Earnings Snapshot
AQ
Compugen : Form 6-K- Fourth quarter and full year 2023 results
PU
Compugen Reports Fourth Quarter and Full Year 2023 Results
PR
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
PR
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. CW9 Stock
  5. News Compugen Ltd.
  6. Press Releases